利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

8 条记录 (耗时 0.012 秒)

    PHARMACEUTICAL COMPOSITIONS COMPRISING POLYMORPHIC FORMS ALPHA, BETA, AND GAMMA OF RIFAXIMIN
    1.
    发明申请
    PHARMACEUTICAL COMPOSITIONS COMPRISING POLYMORPHIC FORMS ALPHA, BETA, AND GAMMA OF RIFAXIMIN 审中-公开
    包含RIFAXIMIN的多形态ALPHA，BETA和GAMMA的药物组合物

    公开(公告)号：US20150182508A1

    公开(公告)日：2015-07-02

    申请号：US14458197

    申请日：2014-08-12

    申请人： ALFA WASSERMANN S.P.A.

    发明人： Giuseppe Claudio VISCOMI ,  Manuela CAMPANA ,  Dario BRAGA ,  Donatella CONFORTINI ,  Vincenzo CANNATA ,  Paolo RIGHI ,  Goffredo ROSINI ,  Denis SEVERINI

    IPC分类号： A61K31/437

    CPC分类号： C07D498/22 ,  A61K31/437 ,  C07B2200/13

    摘要： Crystalline polymorphous forms of rifaximin (INN), referred to as rifaximin α and rifaximin β, and a poorly crystalline form referred to as rifaximin γ, useful in the production of medicaments containing rifaximin for oral and topical use and obtained by means of a crystallization process carried out by hot-dissolving the raw rifaximin in ethyl alcohol and by causing the crystallization of the product by addition of water at a fixed temperature and for a fixed period of time, followed by a drying under controlled conditions until reaching a precise water content in the end product, are the object of the invention.

    摘要翻译： 称为利福昔明（rifaximin）α和利福昔明（rifaximin）的结晶多晶形式，以及称为利福昔明γ的结晶不良形式，可用于生产含有利福昔明用于口服和局部使用并通过结晶获得的药物 通过将生的利福昔明热溶解在乙醇中并通过在固定温度下加入水而使产物结晶并持续一段时间进行，然后在受控条件下干燥直到达到精确的含水量 在最终产品中，是本发明的目的。

    POLYMORPHIC FORMS ALPHA, BETA AND GAMMA OF RIFAXIMIN
    4.
    发明申请
    POLYMORPHIC FORMS ALPHA, BETA AND GAMMA OF RIFAXIMIN 审中-公开
    多聚体形式的阿尔法，BETA和游戏的RIFAXIMIN

    公开(公告)号：US20150175627A1

    公开(公告)日：2015-06-25

    申请号：US14457909

    申请日：2014-08-12

    申请人： ALFA WASSERMANN S.P.A.

    发明人： Giuseppe Claudio VISCOMI ,  Manuela CAMPANA ,  Dario BRAGA ,  Donatella CONFORTINI ,  Vincenzo CANNATA ,  Paolo RIGHI ,  Goffredo ROSINI ,  Denis Severini

    IPC分类号： C07D498/22

    CPC分类号： C07D498/22 ,  C07B2200/13 ,  C07D491/22

    摘要： Crystalline polymorphous forms of rifaximin (INN) antibiotic named rifaximin α and rifaximin β, and a poorly crystalline form named rifaximin γ, useful in the production of medicinal preparations containing rifaximin for oral and topical use and obtained by means of a crystallization carried out by hot-dissolving the raw rifaximin in ethyl alcohol and by causing the crystallization of the product by addition of water at a determinate temperature and for a determinate period of time, followed by a drying carried out under controlled conditions until reaching a settled water content in the end product, are the object of the invention.

    摘要翻译： 结晶多形态的利福昔明（INN）抗生素名为利福昔明α和利福昔明，并且结晶形式名为利福昔明γ，可用于生产含有利福昔明用于口服和局部使用的药物制剂，并通过结晶进行 将生的利福昔明热溶解在乙醇中，并通过在确定的温度下加入水并在一定的时间内引起产物的结晶，然后在受控条件下进行干燥，直到达到沉淀的含水量 最终产品是本发明的目的。

    POLYMORPHOUS FORMS OF RIFAXIMIN, PROCESSES FOR THEIR PRODUCTION AND USE THEREOF IN THE MEDICINAL PREPARATIONS
    7.
    发明申请
    POLYMORPHOUS FORMS OF RIFAXIMIN, PROCESSES FOR THEIR PRODUCTION AND USE THEREOF IN THE MEDICINAL PREPARATIONS 审中-公开
    益生菌多形态，其生产过程及其在药物制剂中的应用

    公开(公告)号：US20160362419A1

    公开(公告)日：2016-12-15

    申请号：US14994079

    申请日：2016-01-12

    申请人： ALFA WASSERMANN S.P.A.

    发明人： Giuseppe Claudio VISCOMI ,  Manuela CAMPANA ,  Donatella CONFORTINI ,  Maria BARBANTI ,  Dario BRAGA

    IPC分类号： C07D491/22 ,  A61K9/00

    CPC分类号： C07D491/22 ,  A61K9/0053 ,  A61K31/437 ,  C07B2200/13 ,  C07D498/22

    摘要： Crystalline polymorphous forms of the rifaximin (INN) antibiotic named rifaximin δ and rifaximin ε useful in the production of medicinal preparations containing rifaximin for oral and topical use and obtained by means of a crystallization process carried out by hot-dissolving the raw rifaximin in ethyl alcohol and by causing the crystallization of the product by addition of water at a determinate temperature and for a determinate period of time, followed by a drying carried out under controlled conditions until reaching a settled water content in the end product, are the object of the invention.

    摘要翻译： 利福昔明（INN）抗生素的结晶多形态称为利福昔明δ和利福昔明ε，其用于制备含有利福昔明用于口服和局部使用的药物制剂，并且通过将原始利福昔明热溶解在乙醇中进行的结晶过程获得 并且通过在确定的温度下加入水并确定一段时间来引起产物的结晶，然后在受控条件下进行干燥直至达到最终产物中的沉降含水量为目的的本发明的目的 。

    POLYMORPHOUS FORMS OF RIFAXIMIN, PROCESSES FOR THEIR PRODUCTION AND USE THEREOF IN THE MEDICINAL PREPARATIONS
    8.
    发明申请
    POLYMORPHOUS FORMS OF RIFAXIMIN, PROCESSES FOR THEIR PRODUCTION AND USE THEREOF IN THE MEDICINAL PREPARATIONS 有权
    益生菌多形态，其生产过程及其在药物制剂中的应用

    公开(公告)号：US20150073007A1

    公开(公告)日：2015-03-12

    申请号：US14262612

    申请日：2014-04-25

    申请人： ALFA WASSERMANN S.P.A.

    发明人： Giuseppe Claudio VISCOMI ,  Manuela CAMPANA ,  Donatella CONFORTINI ,  Maria Miriam BARBANTI ,  Dario BRAGA

    IPC分类号： A61K31/437

    CPC分类号： C07D491/22 ,  A61K9/0053 ,  A61K31/437 ,  C07B2200/13 ,  C07D498/22

    摘要： Crystalline polymorphous forms of the rifaximin (INN) antibiotic named rifaximin δ and rifaximin ε useful in the production of medicinal preparations containing rifaximin for oral and topical use and obtained by means of a crystallization process carried out by hot-dissolving the raw rifaximin in ethyl alcohol and by causing the crystallization of the product by addition of water at a determinate temperature and for a determinate period of time, followed by a drying carried out under controlled conditions until reaching a settled water content in the end product, are the object of the invention.

    摘要翻译： 名为利福昔明δ和利福昔明的利福昔明（INN）抗生素的结晶多形态 可用于生产含有利福昔明用于口服和局部使用的药物制剂，并且通过将原来的利福昔明热溶解在乙醇中进行的结晶方法获得，并通过在确定的温度下加入水来使产物结晶 并且在一段确定的时间段内，随后在受控条件下进行干燥，直到达到最终产品中的沉降含水量为止，是本发明的目的。